Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
CFTR modulation
ELX/TEZ/IVA
airway metagenome
cystic fibrosis
metagenomics
whole-genome sequencing
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
26 10 2022
26 10 2022
Historique:
pubmed:
27
9
2022
medline:
29
10
2022
entrez:
26
9
2022
Statut:
ppublish
Résumé
The introduction of mutation-specific combination therapy with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has substantially improved lung function and quality of life of people with cystic fibrosis (CF). Collecting deep cough swabs and induced sputum, this postapproval study examined the effect of 14- and 50-week treatment with ELX/TEZ/IVA on the airway microbial metagenome of pancreatic- insufficient CF patients aged 12 years and older. Compared to pretreatment, the total bacterial load decreased, the individual species were more evenly distributed in the community, and the individual microbial metagenomes became more similar in their composition. However, the microbial network remained vulnerable to fragmentation. The initial shift of the CF metagenome was attributable to the ELX/TEZ/IVA-mediated gain of CFTR activity followed by a diversification driven by a group of commensals at the 1-year time point that are typical for healthy airways.
Identifiants
pubmed: 36154176
doi: 10.1128/spectrum.01454-22
pmc: PMC9602284
doi:
Substances chimiques
Chloride Channel Agonists
0
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
elexacaftor
RRN67GMB0V
ivacaftor
1Y740ILL1Z
tezacaftor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0145422Références
mSystems. 2020 Dec 1;5(6):
pubmed: 33262240
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1522-1532
pubmed: 33734030
Ann Am Thorac Soc. 2019 Nov;16(11):1375-1382
pubmed: 31319678
PLoS One. 2014 Jun 10;9(6):e98679
pubmed: 24914678
Lancet Respir Med. 2016 Aug;4(8):627-635
pubmed: 27180018
N Engl J Med. 2019 Nov 7;381(19):1809-1819
pubmed: 31697873
Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25
pubmed: 23590265
Sci Rep. 2015 May 14;5:10241
pubmed: 25974282
Eur Respir J. 2018 Jul 11;52(1):
pubmed: 29946004
NPJ Biofilms Microbiomes. 2016 Dec 2;2:4
pubmed: 28649398
J Cyst Fibros. 2021 May;20(3):381-387
pubmed: 33531206
NPJ Biofilms Microbiomes. 2020 Dec 15;6(1):61
pubmed: 33319812
mSystems. 2020 Jul 7;5(4):
pubmed: 32636336
N Engl J Med. 2015 Jul 16;373(3):220-31
pubmed: 25981758
J Bacteriol. 2018 Jan 24;200(4):
pubmed: 29084859
J Cyst Fibros. 2022 Nov;21(6):996-1005
pubmed: 34824018
Front Microbiol. 2014 May 20;5:219
pubmed: 24904535
J Pers Med. 2021 Apr 27;11(5):
pubmed: 33925519
Cell Rep. 2019 Feb 19;26(8):2227-2240.e5
pubmed: 30784601
PLoS One. 2012;7(9):e45001
pubmed: 23049765
J Cyst Fibros. 2013 Mar;12(2):154-64
pubmed: 22951208
Am J Respir Crit Care Med. 2020 May 15;201(10):1193-1208
pubmed: 31860331
Int J Mol Sci. 2017 Jul 29;18(8):
pubmed: 28758937
Microbiome. 2017 Feb 10;5(1):20
pubmed: 28187782
Lancet Respir Med. 2015 Jul;3(7):524-33
pubmed: 26070913
Lancet Respir Med. 2022 Mar;10(3):267-277
pubmed: 34942085
Thorax. 2020 Sep;75(9):780-790
pubmed: 32631930
Semin Respir Crit Care Med. 2019 Dec;40(6):727-736
pubmed: 31887768
F1000Res. 2018 Mar 5;7:272
pubmed: 29707201
Nat Rev Microbiol. 2017 May;15(5):259-270
pubmed: 28316330
PLoS One. 2019 Sep 19;14(9):e0222323
pubmed: 31536536
mSystems. 2020 Jun 23;5(3):
pubmed: 32576651
J Pers Med. 2021 Jul 27;11(8):
pubmed: 34442373
J Cyst Fibros. 2018 Jan;17(1):50-56
pubmed: 29042177
Am J Respir Crit Care Med. 2010 Oct 1;182(7):929-36
pubmed: 20538955
Am J Respir Crit Care Med. 2022 Mar 1;205(5):540-549
pubmed: 34936849
Am J Respir Crit Care Med. 2017 Jun 15;195(12):1617-1628
pubmed: 28222269
Comput Struct Biotechnol J. 2021 Dec 15;20:175-186
pubmed: 35024091
BMC Genomics. 2022 Nov 11;23(1):748
pubmed: 36368923
N Engl J Med. 2011 Nov 3;365(18):1663-72
pubmed: 22047557
Front Microbiol. 2020 Jun 30;11:1463
pubmed: 32695090
PLoS Pathog. 2018 Jan 18;14(1):e1006798
pubmed: 29346420
Thorax. 2017 Dec;72(12):1104-1112
pubmed: 28280235
Eur Respir J. 2017 Nov 16;50(5):
pubmed: 29146601
Ann Am Thorac Soc. 2020 Feb;17(2):212-220
pubmed: 31604026
BMJ Open Respir Res. 2020 Oct;7(1):
pubmed: 33020115
Eur Respir J. 2000 Oct;16(4):749-67
pubmed: 11106223
Front Cell Infect Microbiol. 2020 Apr 28;10:174
pubmed: 32411616
Thorax. 2015 Jan;70(1):74-81
pubmed: 25035125
Nat Immunol. 2019 Oct;20(10):1279-1290
pubmed: 31501577
N Engl J Med. 2015 Jan 22;372(4):351-62
pubmed: 25607428
Microorganisms. 2020 Jul 04;8(7):
pubmed: 32635564
Biochemistry (Mosc). 2020 Jan;85(1):1-10
pubmed: 32079513
ERJ Open Res. 2016 May 09;2(2):
pubmed: 27730195
Microbiome. 2020 Apr 2;8(1):45
pubmed: 32238195
Lancet. 2021 Jun 5;397(10290):2195-2211
pubmed: 34090606
Trends Mol Med. 2019 Dec;25(12):1110-1122
pubmed: 31439509
N Engl J Med. 2021 Aug 26;385(9):815-825
pubmed: 34437784
PLoS Comput Biol. 2017 Feb 21;13(2):e1005404
pubmed: 28222096
Nat Biotechnol. 2017 Sep 12;35(9):833-844
pubmed: 28898207
J Clin Microbiol. 2014 Feb;52(2):425-37
pubmed: 24478471
Int J Mol Sci. 2021 Mar 25;22(7):
pubmed: 33806154
Mediators Inflamm. 2017;2017:5047403
pubmed: 29445257
Thorax. 2020 Dec;75(12):1058-1064
pubmed: 33139451
Nat Commun. 2018 Aug 6;9(1):3096
pubmed: 30082706
Ann Am Thorac Soc. 2019 Dec;16(12):1534-1542
pubmed: 31415187
Expert Rev Respir Med. 2018 Oct;12(10):857-865
pubmed: 30118374
mBio. 2021 Dec 21;12(6):e0314821
pubmed: 34903059
Nat Microbiol. 2020 Feb;5(2):379-390
pubmed: 31959969
Thorax. 2018 Nov;73(11):1016-1025
pubmed: 30135091
N Engl J Med. 2010 Nov 18;363(21):1991-2003
pubmed: 21083385
PLoS One. 2014 Mar 05;9(3):e90934
pubmed: 24599149